A Phase 3 Double-blind,Randomized, Placebo-controlled,Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A Phase 3 Double-blind,Randomized, Placebo-controlled,Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
This study is a multicenter, randomized study in subjects with high cholesterol receiving highly effective statins to assess the efficacy, safety and tolerability of Bococizumab (PF-04950615;RN316) to lower LDL-C.
Inclusion Criteria:
Exclusion Criteria:
Vista, California 92083, United States
Jacksonville, Florida 32204, United States
Philadelphia, Pennsylvania 19104, United States
Katowice, Masovian Voivodeship 40-040, Poland
Warsaw, 02-507, Poland
Uijeongbu-si, Gyeonggi-do 480-717, South Korea
Gangwon-Do, 220-701, South Korea